STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR) has obtained approval for its IVF nutrient solutions in Russia. Approval comprises 35 products. “Russia is one of the markets that we have decided to focus on. Penetration for IVF is relatively low today, but it is assessed that this market can grow faster than average during the coming years” says Nils Sellbom, Director of Sales at Vitrolife
